CA9 and neoplasm: In 6 of the 7 evaluable patients, the modified DC vaccine elicited a broad-based anti-tumor response directed against many tumor antigens including hTERT, G250 and oncofetal antigen, but not against self-proteins that are expressed by normal renal tissues.